{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:35Z","timestamp":1792813415432,"version":"4.5.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00412879"],"award-info":[{"award-number":["RS-2024-00412879"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1C1C2006283"],"award-info":[{"award-number":["2021R1C1C2006283"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","award":["RS-2024-00403169"],"award-info":[{"award-number":["RS-2024-00403169"]}],"id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"publisher","award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neovascular age-related macular degeneration (nAMD) is a major cause of irreversible vision loss in the elderly, driven by choroidal neovascularization and dysregulated vascular endothelial growth factor (VEGF) signaling. While anti-VEGF injections have transformed management, their frequent administration imposes a substantial burden on patients and limits adherence. Adeno-associated virus (AAV)-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment, potentially overcoming these limitations. This review summarizes the rationale for AAV use in ocular gene therapy, compares major delivery routes, and highlights leading clinical candidates, including RGX-314, ADVM-022, 4D-150, and NG101. Advances in vector engineering, promoter optimization, and immune modulation are discussed alongside key challenges such as preexisting immunity and inflammation. Future directions include next-generation capsids, combination regimens, and precision patient selection. Collectively, these developments position AAV-based gene therapy as a promising strategy to redefine the therapeutic landscape of nAMD.<\/jats:p>","DOI":"10.1038\/s41434-026-00595-4","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:42:19Z","timestamp":1770957739000},"page":"383-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["AAV-based gene therapies for neovascular AMD"],"prefix":"10.1038","volume":"33","author":[{"given":"Tae Hee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan You","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yoon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-3592","authenticated-orcid":false,"given":"Hee Chan","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"102322","DOI":"10.1016\/j.arr.2024.102322","volume":"98","author":"P Kumbhar","year":"2024","unstructured":"Kumbhar P, Kolekar K, Vishwas S, Shetti P, Kumbar V, Andreoli Pinto TJ, et al. Treatment avenues for age-related macular degeneration: breakthroughs and bottlenecks. Ageing Res Rev. 2024;98:102322.","journal-title":"Ageing Res Rev"},{"key":"595_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03844-6","volume":"11","author":"Y Hu","year":"2024","unstructured":"Hu Y, Gao Y, Gao W, Luo W, Yang Z, Xiong F, et al. AMD-SD: an optical coherence tomography image dataset for wet AMD lesions segmentation. Sci Data. 2024;11:1014.","journal-title":"Sci Data"},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13287-022-02931-y","volume":"13","author":"L Li","year":"2022","unstructured":"Li L, Yu Y, Lin S, Hu J. Changes in best-corrected visual acuity in patients with dry age-related macular degeneration after stem cell transplantation: systematic review and meta-analysis. Stem Cell Res Ther. 2022;13:237.","journal-title":"Stem Cell Res Ther"},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.3390\/cells11213453","volume":"11","author":"H Helotera","year":"2022","unstructured":"Helotera H, Kaarniranta K. A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration. Cells. 2022;11:3453.","journal-title":"Cells"},{"key":"595_CR5","doi-asserted-by":"crossref","unstructured":"Age-related macular degeneration. Nat Rev Dis Primers. 2021;7:32.","DOI":"10.1038\/s41572-021-00272-3"},{"key":"595_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52315-w","volume":"14","author":"G Boscia","year":"2024","unstructured":"Boscia G, Pozharitskiy N, Grassi MO, Borrelli E, D\u2019Addario M, Alessio G, et al. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD. Sci Rep. 2024;14:1941.","journal-title":"Sci Rep"},{"key":"595_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40266-020-00822-6","volume":"38","author":"JB Kim","year":"2021","unstructured":"Kim JB, Lad EM. Therapeutic options under development for non-neovascular age-related macular degeneration and geographic atrophy. Drugs Aging. 2021;38:17\u201327.","journal-title":"Drugs Aging"},{"key":"595_CR8","doi-asserted-by":"crossref","unstructured":"Singh M, Negi R, Alka, Vinayagam R, Kang SG, Shukla P. Age-related macular degeneration (AMD): pathophysiology, drug targeting approaches, and recent developments in nanotherapeutics. Medicina. 2024;60:1647.","DOI":"10.3390\/medicina60101647"},{"key":"595_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-021-02055-6","volume":"21","author":"P Corazza","year":"2021","unstructured":"Corazza P, D\u2019Alterio FM, Kabbani J, Alam MMR, Mercuri S, Orlans HO, et al. Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. BMC Ophthalmol. 2021;21:300.","journal-title":"BMC Ophthalmol"},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:955\u201363.","journal-title":"JAMA Ophthalmol"},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"1411278","DOI":"10.3389\/fmed.2024.1411278","volume":"11","author":"S Cheng","year":"2024","unstructured":"Cheng S, Zhang S, Huang M, Liu Y, Zou X, Chen X, et al. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med. 2024;11:1411278.","journal-title":"Front Med"},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160:725\u201331 e1.","journal-title":"Am J Ophthalmol"},{"key":"595_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41434-024-00461-1","volume":"31","author":"T Bai","year":"2024","unstructured":"Bai T, Cui B, Xing M, Chen S, Zhu Y, Lin D, et al. Stable inhibition of choroidal neovascularization by adeno-associated virus 2\/8-vectored bispecific molecules. Gene Ther. 2024;31:511\u201323.","journal-title":"Gene Ther"},{"key":"595_CR14","doi-asserted-by":"publisher","first-page":"e6317","DOI":"10.7717\/peerj.6317","volume":"7","author":"Y Katada","year":"2019","unstructured":"Katada Y, Kobayashi K, Tsubota K, Kurihara T. Evaluation of AAV-DJ vector for retinal gene therapy. PeerJ. 2019;7:e6317.","journal-title":"PeerJ"},{"key":"595_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48221-4","volume":"15","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang H, Li Q, Qin Y, Yang S, Li J, et al. An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species. Nat Commun. 2024;15:3780.","journal-title":"Nat Commun"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464\u201388.","journal-title":"Mol Ther"},{"key":"595_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ajo.2025.04.020","volume":"277","author":"B Chiang","year":"2025","unstructured":"Chiang B, Chung YG, Prausnitz MR. Suprachoroidal drug delivery for VEGF suppression in Wet AMD and other diseases with choroidal neovascularization. Am J Ophthalmol. 2025;277:556\u201369.","journal-title":"Am J Ophthalmol"},{"key":"595_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jphs.2025.03.003","volume":"158","author":"A Shirakawa","year":"2025","unstructured":"Shirakawa A, Yasuda H, Nakamura S, Takajo Y, Inamasu S, Yomoda S, et al. The anti-angiogenic effects of arctigenin on choroidal neovascularization pathogenesis. J Pharm Sci. 2025;158:42\u201351.","journal-title":"J Pharm Sci"},{"key":"595_CR19","doi-asserted-by":"crossref","unstructured":"Fragiotta S, Bassis L, Abdolrahimzadeh B, Marino A, Sepe M, Abdolrahimzadeh S. Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents. Int J Mol Sci. 2024;25:4433.","DOI":"10.3390\/ijms25084433"},{"key":"595_CR20","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA, De Falco S, Joussen AM, Sennlaub F, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954.","journal-title":"Prog Retin Eye Res"},{"key":"595_CR21","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.3390\/ijms26083463","volume":"26","author":"ME Ochoa Hern\u00e1ndez","year":"2025","unstructured":"Ochoa Hern\u00e1ndez ME, Lewis-Lujan LM, Burboa Zazueta MG, Del Castillo Castro T, De La Re Vega E, G\u00e1lvez-Ruiz JC, et al. Role of oxidative stress and inflammation in age-related macular degeneration: insights into the retinal pigment epithelium (RPE). Int J Mol Sci. 2025;26:3463.","journal-title":"Int J Mol Sci"},{"key":"595_CR22","first-page":"1535","volume":"16","author":"F Buonfiglio","year":"2024","unstructured":"Buonfiglio F, Korb CA, Stoffelns B, Pfeiffer N, Gericke A. Recent advances in our understanding of age-related macular degeneration: mitochondrial dysfunction, redox signaling, and the complement system. Aging Dis. 2024;16:1535\u201375.","journal-title":"Aging Dis"},{"key":"595_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12929-019-0531-z","volume":"26","author":"CM Chan","year":"2019","unstructured":"Chan CM, Huang DY, Sekar P, Hsu SH, Lin WW. Reactive oxygen species-dependent mitochondrial dynamics and autophagy confer protective effects in retinal pigment epithelial cells against sodium iodate-induced cell death. J Biomed Sci. 2019;26:40.","journal-title":"J Biomed Sci"},{"key":"595_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.18240\/ijo.2025.04.11","volume":"18","author":"OM Gagliardi","year":"2025","unstructured":"Gagliardi OM, Alisi L, Visioli G, Dini F, Albanese GM, Scordari S, et al. OCT predictors of retinal atrophy in neovascular age-related macular degeneration treated with aflibercept. Int J Ophthalmol. 2025;18:648\u201355.","journal-title":"Int J Ophthalmol"},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000516108","volume":"244","author":"DT Wong","year":"2021","unstructured":"Wong DT, Berger AR, Bourgault S, Chen J, Colleaux K, Cruess AF, et al. Imaging biomarkers and their impact on therapeutic decision-making in the management of neovascular age-related macular degeneration. Ophthalmologica. 2021;244:265\u201380.","journal-title":"Ophthalmologica"},{"key":"595_CR26","doi-asserted-by":"crossref","unstructured":"Faatz H, Lommatzsch A. Overview of the use of optical coherence tomography angiography in neovascular age-related macular degeneration. J Clin Med, 2024;13:5042.","DOI":"10.3390\/jcm13175042"},{"key":"595_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"595_CR28","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s40123-024-00983-2","volume":"13","author":"E Debourdeau","year":"2024","unstructured":"Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, et al. Treat-and-extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study from routine clinical practice. Ophthalmol Ther. 2024;13:2343\u201355.","journal-title":"Ophthalmol Ther"},{"key":"595_CR29","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A. Brolucizumab: first approval. Drugs. 2019;79:1997\u20132000.","journal-title":"Drugs"},{"key":"595_CR30","doi-asserted-by":"crossref","unstructured":"Liberski S, Wichrowska M, Kociecki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23:9424.","DOI":"10.3390\/ijms23169424"},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1172\/JCI84923","volume":"126","author":"EA Korhonen","year":"2016","unstructured":"Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest. 2016;126:3495\u2013510.","journal-title":"J Clin Invest"},{"key":"595_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;165:1\u20136.","journal-title":"Am J Ophthalmol"},{"key":"595_CR33","doi-asserted-by":"crossref","unstructured":"Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA. Real-world 10-year outcomes of anti-VEGF therapy for neovascular age-related macular degeneration: a meta-analysis. Clin Exp Ophthalmol. 2025;53:773\u2013790.","DOI":"10.1111\/ceo.14559"},{"key":"595_CR34","unstructured":"Zuber-Laskawiec K, Kubicka-Trzaska A, Karska-Basta I, Pociej-Marciak W, Romanowska-Dixon B. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration. J Physiol Pharmacol. 2019;70:779\u201385."},{"key":"595_CR35","doi-asserted-by":"crossref","unstructured":"Wong DT, Aboobaker S, Maberley D, Sharma S, Yoganathan P. Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025;10:e001967.","DOI":"10.1136\/bmjophth-2024-001967"},{"key":"595_CR36","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559\u201369.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"595_CR37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s40123-025-01140-z","volume":"14","author":"M Shellvarajah","year":"2025","unstructured":"Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D. Adherence to anti-VEGF treatment in patients with neovascular age-related macular degeneration: a real-world study. Ophthalmol Ther. 2025;14:1261\u20139.","journal-title":"Ophthalmol Ther"},{"key":"595_CR38","first-page":"44","volume":"27","author":"D Yorston","year":"2014","unstructured":"Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014;27:44\u20136.","journal-title":"Community Eye Health"},{"key":"595_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78.","journal-title":"Signal Transduct Target Ther"},{"key":"595_CR40","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","volume":"33","author":"AM Nisanov","year":"2025","unstructured":"Nisanov AM, Rivera de Jesus JA, Schaffer DV. Advances in AAV capsid engineering: integrating rational design, directed evolution and machine learning. Mol Ther. 2025;33:1937\u201345.","journal-title":"Mol Ther"},{"key":"595_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","volume":"5","author":"S Ling","year":"2021","unstructured":"Ling S, Yang S, Hu X, Yin D, Dai Y, Qian X, et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nat Biomed Eng. 2021;5:144\u201356.","journal-title":"Nat Biomed Eng"},{"key":"595_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/hum.2016.117","volume":"28","author":"PA Campochiaro","year":"2017","unstructured":"Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, et al. Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study. Hum Gene Ther. 2017;28:99\u2013111.","journal-title":"Hum Gene Ther"},{"key":"595_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41591-023-02789-4","volume":"30","author":"M Migliavacca","year":"2024","unstructured":"Migliavacca M, Barzaghi F, Fossati C, Rancoita PMV, Gabaldo M, Dionisio F, et al. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nat Med. 2024;30:488\u201397.","journal-title":"Nat Med"},{"key":"595_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47866-5","volume":"15","author":"D Cesana","year":"2024","unstructured":"Cesana D, Cicalese MP, Calabria A, Merli P, Caruso R, Volpin M, et al. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID. Nat Commun. 2024;15:3662.","journal-title":"Nat Commun"},{"key":"595_CR45","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMe2409399","volume":"391","author":"CE Dunbar","year":"2024","unstructured":"Dunbar CE. Weighing the risks of lentiviral gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391:1358\u20139.","journal-title":"N Engl J Med"},{"key":"595_CR46","doi-asserted-by":"publisher","first-page":"103802","DOI":"10.1016\/j.cellimm.2018.04.012","volume":"342","author":"A Annoni","year":"2019","unstructured":"Annoni A, Gregori S, Naldini L, Cantore A. Modulation of immune responses in lentiviral vector-mediated gene transfer. Cell Immunol. 2019;342:103802.","journal-title":"Cell Immunol"},{"key":"595_CR47","doi-asserted-by":"crossref","unstructured":"Arsenijevic Y, Berger A, Udry F, Kostic C. Lentiviral vectors for ocular gene therapy. Pharmaceutics. 2022;14:1605.","DOI":"10.3390\/pharmaceutics14081605"},{"key":"595_CR48","unstructured":"Lauer AK, Campochiaro PA, Sohn EH, Kelleher M, Harrop R, Loader J, et al. Phase I Safety and Tolerability Results for RetinoStat\u00ae, a lentiviral vector expressing endostatin and angiostatin, in patients with advanced neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci. 2016;57:12."},{"key":"595_CR49","unstructured":"Chandler S, Campochiaro P, Lauer A, Sohn EH, Stout T, Kelleher M, et al. Results from the Phase I GEM study, evaluating safety and tolerability of subretinallyinjected lentiviral vector (RetinoStat\u00ae) for the treatment of wet age-related macular degeneration (AMD). Invest Ophth Vis Sci. Jun 2015;56:2284."},{"key":"595_CR50","doi-asserted-by":"publisher","first-page":"101295","DOI":"10.1016\/j.omtm.2024.101295","volume":"32","author":"NK Taylor","year":"2024","unstructured":"Taylor NK, Guggenbiller MJ, Mistry PP, King OD, Harper SQ. A self-complementary AAV proviral plasmid that reduces cross-packaging and ITR promoter activity in AAV vector preparations. Mol Ther Methods Clin Dev. 2024;32:101295.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR51","first-page":"1054069","volume":"2","author":"T Suoranta","year":"2022","unstructured":"Suoranta T, Laham-Karam N, Yla-Herttuala S. Strategies to improve the safety profile of AAV vectors. Front. Mol Med. 2022;2:1054069.","journal-title":"Mol Med"},{"key":"595_CR52","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","volume":"32","author":"JH Wang","year":"2024","unstructured":"Wang JH, Zhan W, Gallagher TL, Gao G. Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: a comprehensive review. Mol Ther. 2024;32:4185\u2013207.","journal-title":"Mol Ther"},{"key":"595_CR53","first-page":"1148795","volume":"3","author":"S Koponen","year":"2023","unstructured":"Koponen S, Kokki E, Tamminen T, Yla-Herttuala S. AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery. Front. Drug Deliv. 2023;3:1148795.","journal-title":"Drug Deliv"},{"key":"595_CR54","doi-asserted-by":"crossref","unstructured":"Wang X, Wang T, Lam E, Alvarez D, Sun Y. Ocular vascular diseases: from retinal immune privilege to inflammation. Int J Mol Sci. 2023;24;12090.","DOI":"10.3390\/ijms241512090"},{"key":"595_CR55","doi-asserted-by":"publisher","first-page":"115780","DOI":"10.1016\/j.celrep.2025.115780","volume":"44","author":"Z Peng","year":"2025","unstructured":"Peng Z, Nagarajan V, Horai R, Jittayasothorn Y, Mattapallil MJ, Caspi RR. Ocular immune privilege in action: the living eye imposes unique regulatory and anergic gene signatures on uveitogenic T cells. Cell Rep. 2025;44:115780.","journal-title":"Cell Rep"},{"key":"595_CR56","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1167\/iovs.17-22473","volume":"58","author":"IP Seitz","year":"2017","unstructured":"Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Investig Ophthalmol Vis Sci. 2017;58:5792\u2013801.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/aos.14249","volume":"97","author":"NB Sorensen","year":"2019","unstructured":"Sorensen NB. Subretinal surgery: functional and histological consequences of entry into the subretinal space. Acta Ophthalmol. 2019;97:1\u201323.","journal-title":"Acta Ophthalmol"},{"key":"595_CR58","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/eye.2017.158","volume":"31","author":"K Xue","year":"2017","unstructured":"Xue K, Groppe M, Salvetti AP, MacLaren RE. Technique of retinal gene therapy: delivery of viral vector into the subretinal space. Eye. 2017;31:1308\u201316.","journal-title":"Eye"},{"key":"595_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/ICU.0000000000000660","volume":"31","author":"DA Prado","year":"2020","unstructured":"Prado DA, Acosta-Acero M, Maldonado RS. Gene therapy beyond Luxturna: a new horizon of the treatment for inherited retinal disease. Curr Opin Ophthalmol. 2020;31:147\u201354.","journal-title":"Curr Opin Ophthalmol"},{"key":"595_CR60","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00417-024-06671-y","volume":"263","author":"M Ohji","year":"2025","unstructured":"Ohji M. Submacular hemorrhage: my personal journey to the goal. Graefes Arch Clin Exp Ophthalmol. 2025;263:901\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"595_CR61","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/1673-5374.306063","volume":"16","author":"M Ross","year":"2021","unstructured":"Ross M, Ofri R. The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. Neural Regen Res. 2021;16:1751\u20139.","journal-title":"Neural Regen Res"},{"key":"595_CR62","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ajmg.c.31842","volume":"184","author":"CA Ku","year":"2020","unstructured":"Ku CA, Pennesi ME. The new landscape of retinal gene therapy. Am J Med Genet C Semin Med Genet. 2020;184:846\u201359.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"595_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.59249\/HWID7537","volume":"97","author":"L Banou","year":"2024","unstructured":"Banou L, Sarrafpour S, Teng CC, Liu J. Ocular gene therapy: an overview of viral vectors, immune responses, and future directions. Yale J Biol Med. 2024;97:491\u2013503.","journal-title":"Yale J Biol Med"},{"key":"595_CR64","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.survophthal.2024.05.002","volume":"69","author":"J Trincao-Marques","year":"2024","unstructured":"Trincao-Marques J, Ayton LN, Hickey DG, Marques-Neves C, Guymer RH, Edwards TL, et al. Gene and cell therapy for age-related macular degeneration: a review. Surv Ophthalmol. 2024;69:665\u201376.","journal-title":"Surv Ophthalmol"},{"key":"595_CR65","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1089\/hum.2020.043","volume":"31","author":"IC Han","year":"2020","unstructured":"Han IC, Cheng JL, Burnight ER, Ralston CL, Fick JL, Thomsen GJ, et al. Retinal tropism and transduction of adeno-associated virus vary by serotype and route of delivery (intravitreal, subretinal, or suprachoroidal) in rats. Hum Gene Ther. 2020;31:1288\u201399.","journal-title":"Hum Gene Ther"},{"key":"595_CR66","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","volume":"16","author":"G Yiu","year":"2020","unstructured":"Yiu G, Chung SH, Mollhoff IN, Nguyen UT, Thomasy SM, Yoo J, et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther Methods Clin Dev. 2020;16:179\u201391.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR67","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.omtm.2024.101242","volume":"32","author":"SH Haldrup","year":"2024","unstructured":"Haldrup SH, Fabian-Jessing BK, Jakobsen TS, Lindholm AB, Adsersen RL, Aagaard L, et al. Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model. Mol Ther Methods Clin Dev. 2024;32:101242.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR68","doi-asserted-by":"publisher","first-page":"eadt9354","DOI":"10.1126\/sciadv.adt9354","volume":"11","author":"R Ferla","year":"2025","unstructured":"Ferla R, Pugni E, Lupo M, Tiberi P, Fioretto F, Perota A, et al. Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models. Sci Adv. 2025;11:eadt9354.","journal-title":"Sci Adv"},{"key":"595_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57628-6","volume":"16","author":"Y Fu","year":"2025","unstructured":"Fu Y, He X, Ma L, Gao XD, Liu P, Shi H, et al. In vivo prime editing rescues photoreceptor degeneration in nonsense mutant retinitis pigmentosa. Nat Commun. 2025;16:2394.","journal-title":"Nat Commun"},{"key":"595_CR70","doi-asserted-by":"crossref","unstructured":"Byrne LC, Day TP, Visel M, Strazzeri JA, Fortuny C, Dalkara D, et al. In vivo-directed evolution of adeno-associated virus in the primate retina. JCI Insight. 2020;5:e135112.","DOI":"10.1172\/jci.insight.135112"},{"key":"595_CR71","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/hum.2017.154","volume":"29","author":"LS Carvalho","year":"2018","unstructured":"Carvalho LS, Xiao R, Wassmer SJ, Langsdorf A, Zinn E, Pacouret S, et al. Synthetic adeno-associated viral vector efficiently targets mouse and nonhuman primate retina in vivo. Hum Gene Ther. 2018;29:771\u201384.","journal-title":"Hum Gene Ther"},{"key":"595_CR72","doi-asserted-by":"crossref","unstructured":"He B, Wilson B, Chen SH, Sharma K, Scappini E, Cook M, et al. Molecular engineering of virus tropism. Int J Mol Sci. 2024;25:11094.","DOI":"10.3390\/ijms252011094"},{"key":"595_CR73","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"595_CR74","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1021\/acs.chemrev.1c00260","volume":"121","author":"Y Wang","year":"2021","unstructured":"Wang Y, Xue P, Cao M, Yu T, Lane ST, Zhao H. Directed evolution: methodologies and applications. Chem Rev. 2021;121:12384\u2013444.","journal-title":"Chem Rev"},{"key":"595_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.65.14.1","volume":"65","author":"MA Calton","year":"2024","unstructured":"Calton MA, Croze RH, Burns C, Beliakoff G, Vazin T, Szymanski P, et al. Design and characterization of a novel intravitreal dual-transgene genetic medicine for neovascular retinopathies. Investig Ophthalmol Vis Sci. 2024;65:1.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR76","doi-asserted-by":"publisher","first-page":"e13392","DOI":"10.15252\/emmm.202013392","volume":"13","author":"M Pavlou","year":"2021","unstructured":"Pavlou M, Schon C, Occelli LM, Rossi A, Meumann N, Boyd RF, et al. Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Mol Med. 2021;13:e13392.","journal-title":"EMBO Mol Med"},{"key":"595_CR77","doi-asserted-by":"crossref","unstructured":"Ghauri MS, Ou L. AAV engineering for improving tropism to the central nervous system. Biology. 2023;12:186.","DOI":"10.3390\/biology12020186"},{"key":"595_CR78","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1089\/hum.2020.070","volume":"31","author":"A Frederick","year":"2020","unstructured":"Frederick A, Sullivan J, Liu L, Adamowicz M, Lukason M, Raymer J, et al. Engineered capsids for efficient gene delivery to the retina and cornea. Hum Gene Ther. 2020;31:756\u201374.","journal-title":"Hum Gene Ther"},{"key":"595_CR79","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41434-024-00477-7","volume":"31","author":"M Cui","year":"2024","unstructured":"Cui M, Su Q, Yip M, McGowan J, Punzo C, Gao G, et al. The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2. Gene Ther. 2024;31:489\u201398.","journal-title":"Gene Ther"},{"key":"595_CR80","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/hum.2016.111","volume":"28","author":"PS Ramachandran","year":"2017","unstructured":"Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T, et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther. 2017;28:154\u201367.","journal-title":"Hum Gene Ther"},{"key":"595_CR81","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","volume":"5","author":"D Dalkara","year":"2013","unstructured":"Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5:189ra76.","journal-title":"Sci Transl Med"},{"key":"595_CR82","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/bit.26031","volume":"113","author":"H Khabou","year":"2016","unstructured":"Khabou H, Desrosiers M, Winckler C, Fouquet S, Auregan G, Bemelmans AP, et al. Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol Bioeng. 2016;113:2712\u201324.","journal-title":"Biotechnol Bioeng"},{"key":"595_CR83","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.15252\/emmm.201404077","volume":"6","author":"T Cronin","year":"2014","unstructured":"Cronin T, Vandenberghe LH, Hantz P, Juttner J, Reimann A, Kacso AE, et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med. 2014;6:1175\u201390.","journal-title":"EMBO Mol Med"},{"key":"595_CR84","doi-asserted-by":"publisher","unstructured":"Kotterman M, Beliakoff G, Croze R, Vazin T, Schmitt C, Szymanski P, et al. Directed evolution of AAV targeting primate retina by intravitreal injection identifies R100, a variant demonstrating robust gene delivery and therapeutic efficacy in non-human primates. Preprint at https:\/\/doi.org\/10.1101\/2021.06.24.449775 2021.","DOI":"10.1101\/2021.06.24.449775"},{"key":"595_CR85","doi-asserted-by":"crossref","unstructured":"Artemyev V, Gubaeva A, Paremskaia AI, Dzhioeva AA, Deviatkin A, Feoktistova SG, et al. Synthetic promoters in gene therapy: design approaches, features and applications. Cells. 2024;13:1963.","DOI":"10.3390\/cells13231963"},{"key":"595_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52163-z","volume":"9","author":"H Wang","year":"2019","unstructured":"Wang H, Kunz E, Stoddard GJ, Hauswirth WW, Hartnett ME. Optimal inhibition of choroidal neovascularization by scAAV2 with VMD2 promoter-driven active Rap1a in the RPE. Sci Rep. 2019;9:15732.","journal-title":"Sci Rep"},{"key":"595_CR87","doi-asserted-by":"crossref","unstructured":"Sudharsan R, Murgiano L, Ahuja A, Sato Y, Kwok J, Dolgova N, et al. Novel photoreceptor-specific promoters for gene therapy in mid- to late-stage retinal degeneration. Mol Ther. 2025;33:4320\u201337.","DOI":"10.1016\/j.ymthe.2025.05.020"},{"key":"595_CR88","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41434-022-00380-z","volume":"30","author":"B Nieuwenhuis","year":"2023","unstructured":"Nieuwenhuis B, Laperrousaz E, Tribble JR, Verhaagen J, Fawcett JW, Martin KR, et al. Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters. Gene Ther. 2023;30:503\u201319.","journal-title":"Gene Ther"},{"key":"595_CR89","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.exer.2010.01.011","volume":"90","author":"F Kong","year":"2010","unstructured":"Kong F, Li W, Li X, Zheng Q, Dai X, Zhou X, et al. Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Exp Eye Res. 2010;90:546\u201354.","journal-title":"Exp Eye Res"},{"key":"595_CR90","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/jop.2022.0022","volume":"38","author":"S Toutounchian","year":"2022","unstructured":"Toutounchian S, Ahmadbeigi N, Mansouri V. Retinal and choroidal neovascularization antivascular endothelial growth factor treatments: the role of gene therapy. J Ocul Pharmacol Ther. 2022;38:529\u201348.","journal-title":"J Ocul Pharmacol Ther"},{"key":"595_CR91","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41434-023-00436-8","volume":"31","author":"B Chaqour","year":"2024","unstructured":"Chaqour B, Duong TT, Yue J, Liu T, Camacho D, Dine KE, et al. AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes. Gene Ther. 2024;31:175\u201386.","journal-title":"Gene Ther"},{"key":"595_CR92","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s43856-025-00789-8","volume":"5","author":"A Bernardo-Colon","year":"2025","unstructured":"Bernardo-Colon A, Bighinati A, Parween S, Debnath S, Piano I, Adani E, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. Commun Med. 2025;5:81.","journal-title":"Commun Med"},{"key":"595_CR93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/tvst.13.8.37","volume":"13","author":"N O\u2019Neill","year":"2024","unstructured":"O\u2019Neill N, Meng M, Chaqour B, Dine K, Sarabu N, Pham JC, et al. Comparison of SNCG and NEFH promoter-driven expression of human SIRT1 expression in a mouse model of glaucoma. Transl Vis Sci Technol. 2024;13:37.","journal-title":"Transl Vis Sci Technol"},{"key":"595_CR94","doi-asserted-by":"publisher","first-page":"0717","DOI":"10.34133\/research.0717","volume":"8","author":"Y Cai","year":"2025","unstructured":"Cai Y, Gu Y, Zhang J, Zhu Y, Ma Z, He Q, et al. An engineered intravitreal injection retinal-pigment-epithelium-tropic adeno-associated virus vector expressing a bispecific antibody binding VEGF-A and ANG-2 rescues neovascular age-related macular degeneration in animal models and patients. Research. 2025;8:0717.","journal-title":"Research"},{"key":"595_CR95","first-page":"e74776","volume":"16","author":"S Bidiwala","year":"2024","unstructured":"Bidiwala S. Efficacy of anti-vascular endothelial growth factor (VEGF) therapy for age-related macular degeneration. Cureus. 2024;16:e74776.","journal-title":"Cureus"},{"key":"595_CR96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41433-024-03373-x","volume":"39","author":"JD Shirian","year":"2025","unstructured":"Shirian JD, Shukla P, Singh RP. Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. Eye. 2025;39:40\u201344.","journal-title":"Eye"},{"key":"595_CR97","unstructured":"REGENXBIO. REGENXBIO announces additional positive interim phase I\/IIa and long-term follow-up data of RGX-314 for the treatment of wet AMD. 2021 [cited 2025 August 20]; Available from: https:\/\/ir.regenxbio.com\/news-releases\/news-release-details\/regenxbio-announces-additional-positive-interim-phase-iiia-and\/."},{"key":"595_CR98","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston SM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet. 2024;403:1563\u201373.","journal-title":"Lancet"},{"key":"595_CR99","doi-asserted-by":"crossref","unstructured":"Batur E, Ozdemir S, Durgun ME, Ozsoy Y. Vesicular drug delivery systems: promising approaches in ocular drug delivery. Pharmaceuticals. 2024;17:511.","DOI":"10.3390\/ph17040511"},{"key":"595_CR100","first-page":"1497","volume":"63","author":"AM Khanani","year":"2022","unstructured":"Khanani AM. Suprachoroidal delivery of RGX-314 gene therapy for neovascular AMD: the phase II AAVIATE\u2122 study. Investig Ophthalmol Vis Sci. 2022;63:1497.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR101","unstructured":"Pitcher JD, Eye H. Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: results from the Phase II AAVIATE\u00ae Study. RegenxBio: Rockville, MD, USA, 2024 [cited 2025 October 31]; Available from: https:\/\/www.regenxbio.com\/getattachment\/09eea7b5-fa2a-4474-90e2-19d8670a6f6f\/ABBV-RGX-314-SCSwAMD-AAVIATE_Pitcher_RHE2024_FINAL_approved-1.pdf."},{"key":"595_CR102","unstructured":"Khanani AM. Subretinal delivery of investigational ABBV-RGX-314 as a gene therapy for neovascular AMD: first-time results of a fellow-eye bilateral dosing study. Presented at: American Academy of Ophthalmology Subspecialty Day (Retina), Chicago, IL, USA; 19 October 2024 [cited 2025 October 31]; Available from: https:\/\/www.regenxbio.com\/getattachment\/696f66f4-96f1-4b5b-b5ad-d2870ae7e838\/SR-Fellow-Eye-AAO_Khanani-2024_FINAL_.pdf."},{"key":"595_CR103","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","volume":"27","author":"R Grishanin","year":"2019","unstructured":"Grishanin R, Vuillemenot B, Sharma P, Keravala A, Greengard J, Gelfman C, et al. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol Ther. 2019;27:118\u201329.","journal-title":"Mol Ther"},{"key":"595_CR104","doi-asserted-by":"crossref","unstructured":"Hinsch VG, Boye SL, Boye SE. A comprehensive review of clinically applied adeno-associated virus-based gene therapies for ocular disease. Hum Gene Ther, 2025;36:1301\u201320.","DOI":"10.1089\/hum.2024.252"},{"key":"595_CR105","doi-asserted-by":"publisher","first-page":"102394","DOI":"10.1016\/j.eclinm.2023.102394","volume":"67","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Boyer DS, Wykoff CC, Regillo CD, Busbee BG, Pieramici D, et al. Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. EClinicalMedicine. 2024;67:102394.","journal-title":"EClinicalMedicine"},{"key":"595_CR106","unstructured":"Kiss S, Turpcu A, Bender K, Friedman M, Chung E, Han J. Phase 1 Study of Intravitreal (IVT) gene therapy with ADVM-022 for neovascular AMD (OPTIC Trial): the role of neutralizing antibodies (NAbs). Invest Ophth Vis Sci. 2022;63:306\u2013F0109."},{"key":"595_CR107","unstructured":"Biotechnologies A. Adverum biotechnologies announces positive 52-week LUNA and 4-Year OPTIC results, and provides key pivotal program design elements. 2024 2024 [cited 2025 October 31]; Available from: https:\/\/investors.adverum.com\/press_releases\/news-details\/2024\/Adverum-Biotechnologies-Announces-Positive-52-Week-LUNA-and-4-Year-OPTIC-Results-and-Provides-Key-Pivotal-Program-Design-Elements\/default.aspx."},{"key":"595_CR108","unstructured":"Pieramici DJ, Wykoff CC, Hahn P, et al. Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: Phase 2 LUNA 52-Week Data. Invest Ophth Vis Sci. Jun 2025;66:882."},{"key":"595_CR109","doi-asserted-by":"crossref","unstructured":"Odio-Herrera M, Orozco-Loaiza G, Wu L. Gene therapy in diabetic retinopathy and diabetic macular edema: an update. J Clin Med. 2025;14:3205.","DOI":"10.3390\/jcm14093205"},{"key":"595_CR110","unstructured":"Therapeutics DM. 4DMT highlights robust and durable clinical activity for 4D-150 and design of 4FRONT phase 3 program at 4D-150 wet AMD development day. 2024 [cited 2025 August 22]; Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and\/."},{"key":"595_CR111","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.4103\/IJO.IJO_1120_24","volume":"73","author":"A Yan","year":"2025","unstructured":"Yan A, Hasan N, Chhablani J. Dry and neovascular \u201cwet\u201d age-related macular degeneration: upcoming therapies. Indian J Ophthalmol. 2025;73:S55\u2013S65.","journal-title":"Indian J Ophthalmol"},{"key":"595_CR112","unstructured":"Khanani AM, Hershberger VS, Kay CN, et al. Interim results for the phase 1\/2 PRISM trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration. Invest Ophth Vis Sci. 2023;64:5055."},{"key":"595_CR113","unstructured":"Khanani AM, Hu A, Eichenbaum DA, et al. Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration. Invest Ophth Vis Sci. 2024;65:4356."},{"key":"595_CR114","first-page":"1861","volume":"66","author":"C Kay","year":"2025","unstructured":"Kay C, Khanani AM, Hu A, Eichenbaum DA, Danzig C, Pieramici D, et al. Interim results from the phase 2b population extension cohort in the PRISM clinical trial evaluating 4D-150 in adults with neovascular (wet) age-related macular degeneration. Investig Ophthalmol Vis Sci. 2025;66:1861.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR115","first-page":"2471","volume":"66","author":"S Kim","year":"2025","unstructured":"Kim S, Shim J, Bak J, Yi S, Han JS. Low-dose AAV gene therapy NG101 for wet AMD: preclinical results and ongoing phase 1\/2a trial design. Investig Ophthalmol Vis Sci. 2025;66:2471.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR116","doi-asserted-by":"publisher","first-page":"101366","DOI":"10.1016\/j.omtm.2024.101366","volume":"32","author":"J Shim","year":"2024","unstructured":"Shim J, Kim Y, Bak J, Shin S, Lee K, Hwang YH, et al. Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration. Mol Ther Methods Clin Dev. 2024;32:101366.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR117","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1093\/hmg\/ddz148","volume":"28","author":"C Domenger","year":"2019","unstructured":"Domenger C, Grimm D. Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28:R3\u2013R14.","journal-title":"Hum Mol Genet"},{"key":"595_CR118","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/gt.2014.115","volume":"22","author":"MA Kotterman","year":"2015","unstructured":"Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22:116\u201326.","journal-title":"Gene Ther"},{"key":"595_CR119","doi-asserted-by":"publisher","first-page":"857276","DOI":"10.3389\/fimmu.2022.857276","volume":"13","author":"DA Gross","year":"2022","unstructured":"Gross DA, Tedesco N, Leborgne C, Ronzitti G. Overcoming the challenges imposed by humoral immunity to AAV vectors to achieve safe and efficient gene transfer in seropositive patients. Front Immunol. 2022;13:857276.","journal-title":"Front Immunol"},{"key":"595_CR120","doi-asserted-by":"publisher","first-page":"101363","DOI":"10.1016\/j.omtm.2024.101363","volume":"32","author":"X Shi","year":"2024","unstructured":"Shi X, Bortolussi G, Collaud F, Le Brun PR, Bloemendaal LT, Guerchet N, et al. Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I. Mol Ther Methods Clin Dev. 2024;32:101363.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR121","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82:825\u201330.","journal-title":"Drugs"},{"key":"595_CR122","first-page":"6280","volume":"66","author":"TS Jakobsen","year":"2025","unstructured":"Jakobsen TS, Fabian-Jessing BK, Adsersen RL, Bek T, Aagaard L, Askou AL, et al. AAV-delivered gene therapy combining VEGF-targeting RNAi therapeutics and PEDF expression for age-related macular degeneration. Investig Ophthalmol Vis Sci. 2025;66:6280\u20136280.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR123","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5483\/BMBRep.2024-0182","volume":"58","author":"J Lee","year":"2025","unstructured":"Lee J, Jeong C. Single-molecule perspectives of CRISPR\/Cas systems: target search, recognition, and cleavage. BMB Rep. 2025;58:8\u201316.","journal-title":"BMB Rep"},{"key":"595_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15464","volume":"8","author":"HY Shin","year":"2017","unstructured":"Shin HY, Wang C, Lee HK, Yoo KH, Zeng X, Kuhns T, et al. CRISPR\/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome. Nat Commun. 2017;8:15464.","journal-title":"Nat Commun"},{"key":"595_CR125","doi-asserted-by":"publisher","first-page":"364","DOI":"10.5483\/BMBRep.2025-0073","volume":"58","author":"Y Kim","year":"2025","unstructured":"Kim Y, Choi YH, Kim M, Jang Y, Lee S. Kinetic basis for Cas12a off-target discrimination. BMB Rep. 2025;58:364\u20138.","journal-title":"BMB Rep"},{"key":"595_CR126","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","volume":"560","author":"F Adikusuma","year":"2018","unstructured":"Adikusuma F, Piltz S, Corbett MA, Turvey M, McColl SR, Helbig KJ, et al. Large deletions induced by Cas9 cleavage. Nature. 2018;560:E8\u2013E9.","journal-title":"Nature"},{"key":"595_CR127","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.7150\/thno.89380","volume":"14","author":"BP Dhungel","year":"2024","unstructured":"Dhungel BP, Winburn I, Pereira CDF, Huang K, Chhabra A, Rasko JEJ. Understanding AAV vector immunogenicity: from particle to patient. Theranostics. 2024;14:1260\u201388.","journal-title":"Theranostics"},{"key":"595_CR128","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","volume":"24","author":"D Ail","year":"2022","unstructured":"Ail D, Ren D, Brazhnikova E, Nouvel-Jaillard C, Bertin S, Mirashrafi SB, et al. Systemic and local immune responses to intraocular AAV vector administration in non-human primates. Mol Ther Methods Clin Dev. 2022;24:306\u201316.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR129","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1089\/hum.2024.261","volume":"36","author":"R Watano","year":"2025","unstructured":"Watano R, Ohba K, Sehara Y, Hayashi Y, Saga Y, Urabe M, et al. Limitation of assay sensitivity revealed by the improvement of cell-based assay against various adeno-associated virus serotypes. Hum Gene Ther. 2025;36:914\u201324.","journal-title":"Hum Gene Ther"},{"key":"595_CR130","doi-asserted-by":"publisher","first-page":"8S46","DOI":"10.1016\/S0929-693X(23)00227-0","volume":"30","author":"A Gardin","year":"2023","unstructured":"Gardin A, Ronzitti G. Current limitations of gene therapy for rare pediatric diseases: lessons learned from clinical experience with AAV vectors. Arch Pediatr. 2023;30:8S46\u20138S52.","journal-title":"Arch Pediatr"},{"key":"595_CR131","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biomedicines13020365","volume":"13","author":"CB Kharisova","year":"2025","unstructured":"Kharisova CB, Kitaeva KV, Solovyeva VV, Sufianov AA, Sufianova GZ, Akhmetshin RF, et al. Looking to the future of viral vectors in ocular gene therapy: clinical review. Biomedicines. 2025;13:365.","journal-title":"Biomedicines"},{"key":"595_CR132","doi-asserted-by":"crossref","unstructured":"Wu KY, Gao A, Giunta M, Tran SD. What\u2019s new in ocular drug delivery: advances in suprachoroidal injection since 2023. Pharmaceuticals. 2024;17:1007.","DOI":"10.3390\/ph17081007"},{"key":"595_CR133","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41434-024-00485-7","volume":"31","author":"Q Lu","year":"2024","unstructured":"Lu Q, Wright A, Pan ZH. AAV dose-dependent transduction efficiency in retinal ganglion cells and functional efficacy of optogenetic vision restoration. Gene Ther. 2024;31:572\u20139.","journal-title":"Gene Ther"},{"key":"595_CR134","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.","journal-title":"Front Immunol"},{"key":"595_CR135","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/pnas.1821000116","volume":"116","author":"W Xiong","year":"2019","unstructured":"Xiong W, Wu DM, Xue Y, Wang SK, Chung MJ, Ji X, et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA. 2019;116:5785\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"595_CR136","doi-asserted-by":"publisher","first-page":"1310050","DOI":"10.3389\/fmed.2023.1310050","volume":"10","author":"X Xia","year":"2023","unstructured":"Xia X, Guo X. Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies. Front Med. 2023;10:1310050.","journal-title":"Front Med"},{"key":"595_CR137","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.1016\/j.omtm.2024.101309","volume":"32","author":"T Kontogiannis","year":"2024","unstructured":"Kontogiannis T, Braybrook J, McElroy C, Foy C, Whale AS, Quaglia M, et al. Characterization of AAV vectors: a review of analytical techniques and critical quality attributes. Mol Ther Methods Clin Dev. 2024;32:101309.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR138","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1002\/bit.28412","volume":"120","author":"Q Fu","year":"2023","unstructured":"Fu Q, Polanco A, Lee YS, Yoon S. Critical challenges and advances in recombinant adeno-associated virus (rAAV) biomanufacturing. Biotechnol Bioeng. 2023;120:2601\u201321.","journal-title":"Biotechnol Bioeng"},{"key":"595_CR139","doi-asserted-by":"publisher","first-page":"108433","DOI":"10.1016\/j.biotechadv.2024.108433","volume":"76","author":"F Destro","year":"2024","unstructured":"Destro F, Wu W, Srinivasan P, Joseph J, Bal V, Neufeld C, et al. The state of technological advancement to address challenges in the manufacture of rAAV gene therapies. Biotechnol Adv. 2024;76:108433.","journal-title":"Biotechnol Adv"},{"key":"595_CR140","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/apb.2022.0022","volume":"27","author":"D Eisenman","year":"2022","unstructured":"Eisenman D, Swindle S. Food and Drug Administration guidance on design of clinical trials for gene therapy products with potential for genome integration or genome editing and associated long-term follow-up of research subjects. Appl Biosaf. 2022;27:201\u20139.","journal-title":"Appl Biosaf"},{"key":"595_CR141","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/cpt.3087","volume":"115","author":"M Rohde","year":"2024","unstructured":"Rohde M, Huh S, D\u2019Souza V, Arkin S, Roberts E, McIntosh A. Practical and statistical considerations for the long-term follow-up of gene therapy trial participants. Clin Pharmacol Ther. 2024;115:139\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"595_CR142","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2174\/0113816128286593240226060318","volume":"30","author":"X Fu","year":"2024","unstructured":"Fu X, Suo H, Zhang J, Chen D. Machine-learning-guided directed evolution for AAV capsid engineering. Curr Pharm Des. 2024;30:811\u201324.","journal-title":"Curr Pharm Des"},{"key":"595_CR143","doi-asserted-by":"publisher","first-page":"e2411062","DOI":"10.1002\/advs.202411062","volume":"12","author":"F Tan","year":"2025","unstructured":"Tan F, Dong Y, Qi J, Yu W, Chai R. Artificial intelligence-based approaches for AAV vector engineering. Adv Sci. 2025;12:e2411062.","journal-title":"Adv Sci"},{"key":"595_CR144","doi-asserted-by":"publisher","first-page":"1001263","DOI":"10.3389\/fimmu.2022.1001263","volume":"13","author":"W Shen","year":"2022","unstructured":"Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis. Front Immunol. 2022;13:1001263.","journal-title":"Front Immunol"},{"key":"595_CR145","doi-asserted-by":"crossref","unstructured":"Elmore ZC, Oh DK, Simon KE, Fanous MM, Asokan A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight, 2020;5:e139881.","DOI":"10.1172\/jci.insight.139881"},{"key":"595_CR146","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017;16:635\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"595_CR147","first-page":"2545","volume":"66","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Luo S, Yu X, Qing X. A dual-targeted gene therapy product for the treatment of dry AMD. Investig Ophthalmol Vis Sci. 2025;66:2545\u20132545.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR148","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1167\/iovs.65.14.41","volume":"65","author":"TS Jakobsen","year":"2024","unstructured":"Jakobsen TS, Adsersen RL, Askou AL, Corydon TJ. Functional roles of pigment epithelium-derived factor in retinal degenerative and vascular disorders: a scoping review. Investig Ophthalmol Vis Sci. 2024;65:41.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"595_CR149","doi-asserted-by":"publisher","first-page":"101217","DOI":"10.1016\/j.omtm.2024.101217","volume":"32","author":"M Braun","year":"2024","unstructured":"Braun M, Lange C, Schatz P, Long B, Stanta J, Gorovits B, et al. Preexisting antibody assays for gene therapy: considerations on patient selection cutoffs and companion diagnostic requirements. Mol Ther Methods Clin Dev. 2024;32:101217.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"595_CR150","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41434-022-00353-2","volume":"30","author":"L Cao","year":"2023","unstructured":"Cao L, Ledeboer A, Pan Y, Lu Y, Meyer K. Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials. Gene Ther. 2023;30:150\u20139.","journal-title":"Gene Ther"},{"key":"595_CR151","doi-asserted-by":"publisher","first-page":"1011143","DOI":"10.3389\/fimmu.2022.1011143","volume":"13","author":"RM Ramamurthy","year":"2022","unstructured":"Ramamurthy RM, Atala A, Porada CD, Almeida-Porada G. Organoids and microphysiological systems: promising models for accelerating AAV gene therapy studies. Front Immunol. 2022;13:1011143.","journal-title":"Front Immunol"},{"key":"595_CR152","doi-asserted-by":"crossref","unstructured":"Alsalloum A, Gornostal E, Mingaleva N, Pavlov R, Kuznetsova E, Antonova E, et al. A comparative analysis of models for AAV-mediated gene therapy for inherited retinal diseases. Cells. 2024;13:1706.","DOI":"10.3390\/cells13201706"},{"key":"595_CR153","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13287-023-03564-5","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Sun X, Duan C, Tang S, Chen J. Application of patient-derived induced pluripotent stem cells and organoids in inherited retinal diseases. Stem Cell Res Ther. 2023;14:340.","journal-title":"Stem Cell Res Ther"},{"key":"595_CR154","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.stemcr.2020.05.007","volume":"15","author":"A Lane","year":"2020","unstructured":"Lane A, Jovanovic K, Shortall C, Ottaviani D, Panes AB, Schwarz N, et al. Modeling and rescue of RP2 retinitis pigmentosa using iPSC-derived retinal organoids. Stem Cell Rep. 2020;15:67\u201379.","journal-title":"Stem Cell Rep"},{"key":"595_CR155","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.stemcr.2023.05.008","volume":"18","author":"N Boon","year":"2023","unstructured":"Boon N, Lu X, Andriessen CA, Moustakas I, Buck TM, Freund C, et al. AAV-mediated gene augmentation therapy of CRB1 patient-derived retinal organoids restores the histological and transcriptional retinal phenotype. Stem Cell Rep. 2023;18:1388.","journal-title":"Stem Cell Rep"},{"key":"595_CR156","doi-asserted-by":"publisher","unstructured":"Kaiser VM, Gonzalez-Cordero A. Organoids \u2013 the future of pre-clinical development of AAV gene therapy for CNS disorders. Gene Ther 2025. https:\/\/doi.org\/10.1038\/s41434-025-00527-8.","DOI":"10.1038\/s41434-025-00527-8"},{"key":"595_CR157","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/hum.2017.179","volume":"29","author":"LA Wiley","year":"2018","unstructured":"Wiley LA, Burnight ER, Kaalberg EE, Jiao C, Riker MJ, Halder JA, et al. Assessment of adeno-associated virus serotype tropism in human retinal explants. Hum Gene Ther. 2018;29:424\u201336.","journal-title":"Hum Gene Ther"},{"key":"595_CR158","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ceo.13434","volume":"47","author":"A Murali","year":"2019","unstructured":"Murali A, Ramlogan-Steel CA, Andrzejewski S, Steel JC, Layton CJ. Retinal explant culture: a platform to investigate human neuroretina. Clin Exp Ophthalmol. 2019;47:274\u201385.","journal-title":"Clin Exp Ophthalmol"},{"key":"595_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49112-2","volume":"13","author":"A Westhaus","year":"2023","unstructured":"Westhaus A, Eamegdool SS, Fernando M, Fuller-Carter P, Brunet AA, Miller AL, et al. AAV capsid bioengineering in primary human retina models. Sci Rep. 2023;13:21946.","journal-title":"Sci Rep"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00595-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:02:52Z","timestamp":1786611772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00595-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":159,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00595-4","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}